- India’s Department of Biotechnology (DBT) has announced the approval of Pune-based Gennova Biopharmaceuticals for emergency use authorization from the Drugs Controller General of India (DCGI) for its mRNA COVID-19 booster vaccine, GEMCOVAC-OM.
- The vaccine, designed specifically against the Omicron variant of SARS-CoV2, has shown promising results in phase 3 clinical trials, indicating its potential to prevent future waves of the pandemic.
- With the emergence of the Omicron variant of SARS-CoV2 and the limited efficacy shown by original vaccines against this lineage, a booster dose has become essential.
- GEMCOVAC-OM is specifically designed to counter the Omicron variant and is expected to address the gap left by existing vaccines.
Tags:
Science
